BRAF and neoplasm: Although small-molecule inhibitors of oncogenic BRAF have proven highly successful for the clinical treatment of several tumor types, atypical (non-V600E) BRAF mutations and BRAF- dependent acquired resistance remain significant challenges and unmet medical needs, which could be targeted using ES-inducing strategies [63].